Apolipoprotein A-I: Insights from redox proteomics for its role in neurodegeneration

Proteomics - Clinical Applications

Volumn 7, Issue 1-2, 2013, Pages 109-122

  Keeney, Jeriel T R ^a   Swomley, Aaron M ^a   Förster, Sarah ^a,b   Harris, Jessica L ^a   Sultana, Rukhsana ^a   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer disease; Apolipoprotein A I; Neurodegeneration; Tumor necrosis factor

Indexed keywords

4 HYDROXYNONENAL; ABC TRANSPORTER A1; ACROLEIN; ANTHRACYCLINE; APOLIPOPROTEIN A1; CHOLESTEROL; DOXORUBICIN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTEIN KINASE C ZETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALZHEIMER DISEASE; APOPTOSIS; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CAUSAL ATTRIBUTION; CHOLESTEROL TRANSPORT; COGNITIVE DEFECT; CYTOKINE RELEASE; DISEASE MARKER; DOWN SYNDROME; HUMAN; LEUKEMIA; LIPID PEROXIDATION; LIPID TRANSPORT; NERVE DEGENERATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; SOLID TUMOR;

ANIMALS; APOLIPOPROTEINS; BIOLOGICAL MARKERS; HUMANS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; PROTEOMICS;

EID: 84872717635     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200087     Document Type: Review

References (148)

1. Davidsson, P., Sjogren, M., The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis. Markers 2005, 21, 81-92.
2. Wang, E. S., Sun, Y., Guo, J. G., Gao, X. et al., Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. Acta Neurol. Scand. 2010, 122, 350-359.
3. Aluise, C. D., Sowell, R. A., Butterfield, D. A., Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim. Biophys. Acta 2008, 1782, 549-558.
4. Taurines, R., Dudley, E., Grassl, J., Warnke A. et al., Proteomic research in psychiatry. J. Psychopharmacol. 2011, 25, 151-196.
5. Butterfield, D. A., Stadtman, E. R., Protein oxidation processes in aging brain. Cell Aging Gerontol. 1997, 2, 161-191.
6. Dalle-Donne, I., Scaloni, A., Giustarini, D., Cavarra, E. et al., Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom. Rev. 2005, 24, 55-99.
7. Butterfield, D. A., Castegna, A., Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders. Amino Acids 2003, 25, 419-425.
8. Butterfield, D. A., Boyd-Kimball, D., Castegna, A., Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J. Neurochem. 2003, 86, 1313-1327.
9. Butterfield, D. A., Dalle-Donne, I., Redox proteomics. Antioxid. Redox. Signal. 2012, 17, 1487-1489.
10. Dalle-Donne, I., Scaloni, A., Butterfield, D. A., Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases, John Wiley & Sons, Hoboken, NJ, 2006.
11. Hansson, S. F., Puchades, M., Blennow, K., Sjögren, M. et al., Validation of a prefractionation method followed by two-dimensional electrophoresis-Applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Science 2004, 2, 7.
12. Quazi, F., Molday, R. S., Lipid transport by mammalian ABC proteins. Essays Biochem. 2011, 50, 265-290.
13. Hyka, N., Dayer, J. M., Modoux, C., Kohno, T. et al., Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001, 97, 2381-2389.
14. Rader, D. J., Daugherty, A., Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008, 451, 904-913.
15. Tape, C., Kisilevsky, R., Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis. Biochim. Biophys. Acta 1990, 1043, 295-300.
16. Saito, K., Seishima, M., Heyes, M. P., Song, H. et al., Marked increases in concentrations of apolipoprotein in the cerebrospinal fluid of poliovirus-infected macaques: relations between apolipoprotein concentrations and severity of brain injury. Biochem. J. 1997, 321 (Pt 1), 145-149.
17. Liscum, L., Underwood, K. W., Intracellular cholesterol transport and compartmentation. J. Biol. Chem. 1995, 270, 15443-15446.
18. Waarts, B. L., Bittman, R., Wilschut, J., Sphingolipid and cholesterol dependence of alphavirus membrane fusion. Lack of correlation with lipid raft formation in target liposomes. J. Biol. Chem. 2002, 277, 38141-38147.
19. Shadan, S., James, P. S., Howes, E. A., Jones, R., Cholesterol efflux alters lipid raft stability and distribution during capacitation of boar spermatozoa. Biol. Reprod. 2004, 71, 253-265.
20. Oh, H. Y., Lee, E. J., Yoon, S., Chung, B. H. et al., Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction. The Prostate 2007, 67, 1061-1069.
21. Chaudhuri, A., Chattopadhyay, A., Transbilayer organization of membrane cholesterol at low concentrations: implications in health and disease. Biochim. Biophys. Acta 2011, 1808, 19-25.
22. Dominiczak, M. H., Risk factors for coronary disease: the time for a paradigm shift? Clin. Chem. Lab. Med.: CCLM/FESCC 2001, 39, 907-919.
23. Dominiczak, M. H., Caslake, M. J., Apolipoproteins: metabolic role and clinical biochemistry applications. Annals of Clin. Biochem. 2011, 48, 498-515.
24. Hill, S. A., McQueen, M. J., Reverse cholesterol transport-a review of the process and its clinical implications. Clin. Biochem. 1997, 30, 517-525.
25. Yang, R., Li, L., Seidelmann, S. B., Shen, G. Q. et al., A genome-wide linkage scan identifies multiple quantitative trait loci for HDL-cholesterol levels in families with premature CAD and MI. J. Lipid Res. 2010, 51, 1442-1451.
26. Zhao, G. J., Yin, K., Fu, Y. C., Tang, C. K., The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids. Mol. Med. 2012, 18, 149-158.
27. Cucuianu, M., Coca, M., Hancu, N., Reverse cholesterol transport and atherosclerosis. A mini review. Romanian J. Int. Med. Revue Roumaine De Medecine Interne 2007, 45, 17-27.
28. Bencharif, K., Hoareau, L., Murumalla, R. K., Tarnus, E. et al., Effect of ApoA-I on cholesterol release and apoE secretion in human mature adipocytes. Lipids in Health and Disease 2010, 9, 75.
29. Undurti, A., Huang, Y., Lupica, J. A., Smith, J. D. et al., Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 2009, 284, 30825-30835.
30. Butterfield, D. A., Bader Lange, M. L., Sultana, R., Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801, 924-929.
31. Kim, H. Y., Tallman, K. A., Liebler, D. C., Porter, N. A., An azido-biotin reagent for use in the isolation of protein adducts of lipid-derived electrophiles by streptavidin catch and photorelease. Mol. Cell Proteomics 2009, 8, 2080-2089.
32. Liebler, D. C., Protein damage by reactive electrophiles: targets and consequences. Chem. Res. Toxicol 2008, 21, 117-128.
33. Subramaniam, R., Roediger, F., Jordan, B., Mattson, M. P. et al., The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 1997, 69, 1161-1169.
34. Szapacs, M. E., Kim, H. Y., Porter, N. A., Liebler, D. C., Identification of proteins adducted by lipid peroxidation products in plasma and modifications of apolipoprotein A1 with a novel biotinylated phospholipid probe. J. Proteome Res. 2008, 7, 4237-4246.
35. Vergeer, M., Holleboom, A. G., Kastelein, J. J., Kuivenhoven, J. A., The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J. Lipid Res. 2010, 51, 2058-2073.
36. Vaughan, A. M., Tang, C., Oram, J. F., ABCA1 mutants reveal an interdependency between lipid export function, ApoA-I binding activity, and Janus kinase 2 activation. J. Lipid Res. 2009, 50, 285-292.
37. Tang, C., Vaughan, A. M., Oram, J. F., Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J. Biolog. Chem. 2004, 279, 7622-7628.
38. Tang, C., Vaughan, A. M., Anantharamaiah, G. M., Oram, J. F., Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J. Lipid Res. 2006, 47, 107-114.
39. Tsukamoto, K., Hirano, K., Tsujii, K., Ikegami, C. et al., ATP-binding cassette transporter-1 induces rearrangement of actin cytoskeletons possibly through Cdc42/N-WASP. Biochem. Biophys. Res. Comm. 2001, 287, 757-765.
40. Iwamoto, N., Lu, R., Tanaka, N., Abe-Dohmae, S. et al., Calmodulin interacts with ATP binding cassette transporter A1 to protect from calpain-mediated degradation and upregulates high-density lipoprotein generation. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1446-1452.
41. Matsunaga, T., Hiasa, Y., Yanagi, H., Maeda, T. et al., Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc. Nat. Acad. Sci. USA 1991, 88, 2793-2797.
42. Yin, K., Deng, X., Mo, Z. C., Zhao, G. J. et al., Tristetraprolin-dependent post-transcriptional regulation of inflammatory cytokine mRNA expression by apolipoprotein A-I: role of ATP-binding membrane cassette transporter A1 and signal transducer and activator of transcription 3. J. Biol. Chem. 2011, 286, 13834-13845.
43. Murray, P. J., Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr. Op. Pharmacol. 2006, 6, 379-386.
44. Tang, C., Liu, Y., Kessler, P. S., Vaughan, A. M. et al., The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J. Biol. Chem. 2009, 284, 32336-32343.
45. Jeon, K. I., Jono, H., Miller, C. L., Cai, Y. et al., Ca2+/calmodulin-stimulated PDE1 regulates the beta-catenin/TCF signaling through PP2A B56 gamma subunit in proliferating vascular smooth muscle cells. FEBS J. 2010, 277, 5026-5039.
46. Yang, J. H., Dai, X. Y., Ou, X., Hao, X. R. et al., Effect of apolipoprotein A-I on expression and function of ATP-binding cassette transporter A1 through PKA signaling. Prog. Biochem. Biophys. 2007, 34, 611-619.
47. Hu, Y. W., Ma, X., Li, X. X., Liu, X. H. et al., Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling pathway in THP-1 macrophage-derived foam cells. Atherosclerosis 2009, 204, e35-e43.
48. Yamauchi, Y., Hayashi, M., Abe-Dohmae, S., Yokoyama, S., Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J. Biol. Chem. 2003, 278, 47890-47897.
49. Yamauchi, Y., Chang, C. C., Hayashi, M., Abe-Dohmae, S. et al., Intracellular cholesterol mobilization involved in the ABCA1/apolipoprotein-mediated assembly of high density lipoprotein in fibroblasts. J. Lipid Res. 2004, 45, 1943-1951.
50. Chen, X., Zhao, Y., Guo, Z., Zhou, L. et al., Transcriptional regulation of ATP-binding cassette transporter A1 expression by a novel signaling pathway. J. Biol. Chem. 2011, 286, 8917-8923.
51. Zheng, L., Nukuna, B., Brennan, M. L., Sun, M. et al., Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 2004, 114, 529-541.
52. Wu, Z., Wagner, M. A., Zheng, L., Parks, J. S. et al., The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat. Struct. Mol. Biol. 2007, 14, 861-868.
53. Helbecque, N., Codron, V., Cottel, D., Amouyel, P., An apolipoprotein A-I gene promoter polymorphism associated with cognitive decline, but not with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2008, 25, 97-102.
54. Schneider-Brachert, W., Tchikov, V., Neumeyer, J., Jakob, M. et al., Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004, 21, 415-428.
55. Badiola, N., Malagelada, C., Llecha, N., Hidalgo, J. et al., Activation of caspase-8 by tumour necrosis factor receptor 1 is necessary for caspase-3 activation and apoptosis in oxygen-glucose deprived cultured cortical cells. Neurobiol. Dis. 2009, 35, 438-447.
56. Selmaj, K. W., Farooq, M., Norton, W. T., Raine, C. S. et al., Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J. Immunol. 1990, 144, 129-135.
57. Gupta, S., Bi, R., Kim, C., Chiplunkar, S. et al., Role of NF-kappaB signaling pathway in increased tumor necrosis factor-alpha-induced apoptosis of lymphocytes in aged humans. Cell Death Diff. 2005, 12, 177-183.
58. Rubio-Perez, J. M., Morillas-Ruiz, J. M., A review: inflammatory process in Alzheimer's disease, role of cytokines. Sci. World J. 2012, 2012, 756357.
59. MacEwan, D. J., TNF receptor subtype signalling: differences and cellular consequences. Cell. Signal 2002, 14, 477-492.
60. Wajant, H., Pfizenmaier, K., Scheurich, P., Tumor necrosis factor signaling. Cell Death Diff. 2003, 10, 45-65.
61. Song, H. Y., Regnier, C. H., Kirschning, C. J., Goeddel, D. V. et al., Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc. Nat. Acad. Sci. USA 1997, 94, 9792-9796.
62. Liu, Z. G., Hsu, H., Goeddel, D. V., Karin, M., Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996, 87, 565-576.
63. Chen, G., Goeddel, D. V., TNF-R1 signaling: a beautiful pathway. Science 2002, 296, 1634-1635.
64. Nishitoh, H., Saitoh, M., Mochida, Y., Takeda, K. et al., ASK1 is essential for JNK/SAPK activation by TRAF2. Molec. Cell 1998, 2, 389-395.
65. Takeuchi, H., Jin, S., Wang, J., Zhang, G. et al., Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem. 2006, 281, 21362-21368.
66. Tangpong, J., Sompol, P., Vore, M., St Clair, W. et al., Tumor necrosis factor alpha-mediated nitric oxide production enhances manganese superoxide dismutase nitration and mitochondrial dysfunction in primary neurons: an insight into the role of glial cells. Neuroscience 2008, 151, 622-629.
67. Boston-Howes, W., Gibb, S. L., Williams, E. O., Pasinelli, P. et al., Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J. Biol. Chem. 2006, 281, 14076-14084.
68. Sitcheran, R., Gupta, P., Fisher, P. B., Baldwin, A. S., Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression. EMBO J. 2005, 24, 510-520.
69. Zou, J. Y., Crews, F. T., TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res. 2005, 1034, 11-24.
70. Kogo, J., Takeba, Y., Kumai, T., Kitaoka, Y. et al., Involvement of TNF-alpha in glutamate-induced apoptosis in a differentiated neuronal cell line. Brain Res. 2006, 1122, 201-208.
71. Stellwagen, D., Beattie, E. C., Seo, J. Y., Malenka, R. C., Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J. Neurosci. 2005, 25, 3219-3228.
72. Aluise, C. D., Miriyala, S., Noel, T., Sultana, R. et al., 2-mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic. Biol. Med. 2011, 50, 1630-1638.
73. Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N., Murtagh, F. R., An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin. Anat. 1995, 8, 429-431.
74. Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C. et al., Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 1986, 261, 6084-6089.
75. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G. et al., Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 1985, 82, 4245-4249.
76. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M. et al., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325, 733-736.
77. Goldgaber, D., Lerman, M. I., McBride, O. W., Saffiotti, U. et al., Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987, 235, 877-880.
78. Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. et al., Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987, 235, 880-884.
79. Butterfield, D. A., Reed, T., Newman, S. F., Sultana, R., Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 2007, 43, 658-677.
80. Sultana, R., Boyd-Kimball, D., Poon, H. F., Cai, J. et al., Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging 2006, 27, 1564-1576.
81. Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S. et al., Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 1989, 24, 173-182.
82. Carter, C. J., Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem. Int. 2007, 50, 12-38.
83. Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M. et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90, 1977-1981.
84. Scarmeas, N., Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I? Am. J. Epidemiol. 2007, 165, 993-997.
85. Evans, R. M., Emsley, C. L., Gao, S., Sahota, A. et al., Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000, 54, 240-242.
86. Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T. et al., Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J. Biol. Chem. 2004, 279, 44945-44954.
87. Yao, Z. X., Papadopoulos, V., Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J. 2002, 16, 1677-1679.
88. Kurata, T., Miyazaki, K., Kozuki, M., Panin, V. L. et al., Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res. 2011, 1371, 161-170.
89. Haag, M. D., Hofman, A., Koudstaal, P. J., Stricker, B. H. et al., Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiat. 2009, 80, 13-17.
90. Sparks, D. L., Connor, D. J., Sabbagh, M. N., Petersen, R. B. et al., Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's disease cholesterol-lowering treatment (ADCLT) trial. Acta Neurol. Scand. 2006, 185, 3-7.
91. Hajjar, I., Schumpert, J., Hirth, V., Wieland, D. et al., The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57, M414-M418.
92. Butterfield, D. A., Atorvastatin and Abeta(1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease. Exp. Neurol. 2011, 228, 15-18.
93. Butterfield, D. A., Barone, E., Di Domenico, F., Cenini, G. et al., Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int. J. Neuropsychopharmacol. 2012, 15, 981-987.
94. Butterfield, D. A., Barone, E., Mancuso, C., Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol. Res. 2011, 64, 180-186.
95. Barone, E., Cenini, G., Di Domenico, F., Martin, S. et al., Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol. Res. 2011, 63, 172-180.
96. Kawano, M., Kawakami, M., Otsuka, M., Yashima, H. et al., Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. Clin. Chim. Acta 1995, 239, 209-211.
97. Merched, A., Xia, Y., Visvikis, S., Serot, J. M. et al., Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging. 2000, 21, 27-30.
98. Liu, H. C., Hu, C. J., Chang, J. G., Sung, S. M. et al., Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006, 21, 155-161.
99. Saczynski, J. S., White, L., Peila, R. L., Rodriguez, B. L. et al., The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am. J. Epidemiol. 2007, 165, 985-992.
100. Song, H., Saito, K., Seishima, M., Noma, A. et al., Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease. Neurosci. Lett. 1997, 231, 175-178.
101. Puchades, M., Hansson, S. F., Nilsson, C. L., Andreasen, N. et al., Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res. 2003, 118, 140-146.
102. Castano, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A. et al., Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res. 2006, 28, 155-163.
103. Golabek, A., Marques, M. A., Lalowski, M., Wisniewski, T., Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci. Lett. 1995, 191, 79-82.
104. Wisniewski, T., Golabek, A. A., Kida, E., Wisniewski, K. E. et al., Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am. J. Pathol. 1995, 147, 238-244.
105. Koldamova, R. P., Lefterov, I. M., Lefterova, M. I., Lazo, J. S., Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 2001, 40, 3553-3560.
106. Lewis, T. L., Cao, D., Lu, H., Mans, R. A. et al., Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J. Biol. Chem. 2010, 285, 36958-36968.
107. Lefterov, I., Fitz, N. F., Cronican, A. A., Fogg, A. et al., Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J. Biol. Chem. 2010, 285, 36945-36957.
108. Wang, J., Dickson, D. W., Trojanowski, J. Q., Lee, V. M., The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 1999, 158, 328-337.
109. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J. et al., Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46, 860-866.
110. Perluigi, M., Butterfield, D. A., Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia. Curr. Gerontol. Geriatr. Res. 2012, 2012, 724904.
111. Lejeune, J., Gautier, M., Turpin, R., (Study of somatic chromosomes from 9 mongoloid children). C R Hebd Seances Acad. Sci. 1959, 248, 1721-1722.
112. Schupf, N., Sergievsky, G. H., Genetic and host factors for dementia in Down's syndrome. Br. J. Psychiat. 2002, 180, 405-410.
113. Schochet, S. S., Jr., Lampert, P. W., McCormick, W. F., Neurofibrillary tangles in patients with Down's syndrome: a light and electron microscopic study. Acta Neuropathol. 1973, 23, 342-346.
114. Zana, M., Janka, Z., Kalman, J., Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Neurobiol. Aging 2007, 28, 648-676.
115. Cenini, G., Dowling, A. L., Beckett, T. L., Barone, E. et al., Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim. Biophys. Acta 2012, 1822, 130-138.
116. Busciglio, J., Yankner, B. A., Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995, 378, 776-779.
117. Perluigi, M., Di Domenico, F., Fiorini, A., Cocciolo, A. et al., Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Proteomics Clin. Appl. 2011, 5, 167-178.
118. Feeney, M. B., Schoneich, C., Tyrosine modifications in aging. Antioxid. Redox Signal. 2012, 17, 1571-1579.
119. Kolla, V., Jeno, P., Moes, S., Tercanli, S. et al., Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ). J. Biomed. Biotechnol. 2010, 2010, 952047.
120. Kang, Y., Dong, X., Zhou, Q., Zhang, Y. et al., Identification of novel candidate maternal serum protein markers for Down syndrome by integrated proteomic and bioinformatic analysis. Prenat. Diagn. 2012, 32, 284-292.
121. Koster, M. P., Pennings, J. L., Imholz, S., Rodenburg, W. et al., Bead-based multiplexed immunoassays to identify new biomarkers in maternal serum to improve first trimester Down syndrome screening. Prenat. Diagn. 2009, 29, 857-862.
122. Chen, Y. C., Wang, P. W., Pan, T. L., Wallace, C. G. et al., Proteomic analysis of Down's syndrome patients with gout. Clin. Chim. Acta 2006, 369, 89-94.
123. Park, J., Cha, D. H., Jung, J. W., Kim, Y. H. et al., Comparative proteomic analysis of human amniotic fluid supernatants with Down syndrome using mass spectrometry. J. Microbiol. Biotechnol. 2010, 20, 959-967.
124. Nagalla, S. R., Canick, J. A., Jacob, T., Schneider, K. A. et al., Proteomic analysis of maternal serum in Down syndrome: identification of novel protein biomarkers. J. Proteome Res. 2007, 6, 1245-1257.
125. Olanow, C. W., Tatton, W. G., Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 1999, 22, 123-144.
126. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M. et al., Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 1996, 93, 2696-2701.
127. Alam, Z. I., Daniel, S. E., Lees, A. J., Marsden, D. C. et al., A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 1997, 69, 1326-1329.
128. Kikuchi, A., Takeda, A., Onodera, H., Kimpara, T. et al., Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis. 2002, 9, 244-248.
129. Seet, R. C., Lee, C. Y., Lim, E. C., Tan, J. J. et al., Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic. Biol. Med. 2010, 48, 560-566.
130. Lee, C. Y., Seet, R. C., Huang, S. H., Long, L. H. et al., Different patterns of oxidized lipid products in plasma and urine of dengue fever, stroke, and Parkinson's disease patients: cautions in the use of biomarkers of oxidative stress. Antioxid. Redox Signal 2009, 11, 407-420.
131. Jenner, P., Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53 Suppl 3, S26-S36; discussion S36-28.
132. Yin, G. N., Lee, H. W., Cho, J. Y., Suk, K., Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res. 2009, 1265, 158-170.
133. Zhang, X., Yin, X., Yu, H., Liu, X. et al., Quantitative proteomic analysis of serum proteins in patients with Parkinson's disease using an isobaric tag for relative and absolute quantification labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. Analyst. 2012, 137, 490-495.
134. Raffa, R. B., Duong, P. V., Finney, J., Garber, D. A. et al., Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy? J. Clin. Pharm. Ther. 2006, 31, 129-138.
135. Bachur, N. R., Gordon, S. L., Gee, M. V., Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol. Pharmacol. 1977, 13, 901-910.
136. Deres, P., Halmosi, R., Toth, A., Kovacs, K. et al., Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound. J. Cardiovasc Pharmacol. 2005, 45, 36-43.
137. Fornari, F. A., Randolph, J. K., Yalowich, J. C., Ritke, M. K. et al., Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol. 1994, 45, 649-656.
138. Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A. et al., Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol. Interv. 2007, 7, 147-156.
139. Jungsuwadee, P., Cole, M. P., Sultana, R., Joshi, G. et al., Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Mol. Cancer Ther. 2006, 5, 2851-2860.
140. Aluise, C. D., Sultana, R., Tangpong, J., Vore, M. et al., Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv. Exp. Med. Biol. 2010, 678, 147-156.
141. Gutierrez, E. G., Banks, W. A., Kastin, A. J., Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J. Neuroimmunol. 1993, 47, 169-176.
142. Osburg, B., Peiser, C., Domling, D., Schomburg, L. et al., Effect of endotoxin on expression of TNF receptors and transport of TNF-alpha at the blood-brain barrier of the rat. Am. J. Physiol. Endocrinol. Metab. 2002, 283, E899-E908.
143. Tangpong, J., Cole, M. P., Sultana, R., Joshi, G. et al., Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol. Dis. 2006, 23, 127-139.
144. Tangpong, J., Cole, M. P., Sultana, R., Estus, S. et al., Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J. Neurochem. 2007, 100, 191-201.
145. Dammann, O., Durum, S., Leviton, A., Do white cells matter in white matter damage? Trends Neurosci. 2001, 24, 320-324.
146. Wang, L. W., Tu, Y. F., Huang, C. C., Ho, C. J., JNK signaling is the shared pathway linking neuroinflammation, blood-brain barrier disruption, and oligodendroglial apoptosis in the white matter injury of the immature brain. J. Neuroinflammation 2012, 9, 175.
147. Figiel, I., Dzwonek, K., TNFalpha and TNF receptor 1 expression in the mixed neuronal-glial cultures of hippocampal dentate gyrus exposed to glutamate or trimethyltin. Brain Res. 2007, 1131, 17-28.
148. Dopp, J. M., Mackenzie-Graham, A., Otero, G. C., Merrill, J. E., Differential expression, cytokine modulation, and specific functions of type-1 and type-2 tumor necrosis factor receptors in rat glia. J. Neuroimmunol. 1997, 75, 104-112.